Consistent with trials evaluating other cholinesterase inhibitors, rivastigmine did not provide consistent efficacy in probable VaD. The efficacy apparent on cognitive outcomes was derived from effects in older patients likely to have concomitant Alzheimer pathology. This is supportive of an existing argument that the putative cholinergic deficit in VaD reflects the presence of concomitant Alzheimer pathology.
No takes yet. Share an insight, caveat, or question.
Ballard et al. (2008) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: